Ultrasound Guided Local Infiltration Analgesia for Hip Arthroscopy

Study Overview
=================
Brief Summary
-----------------
This study is being undertaken to compare the pain control using either bupivacaine versus liposomal bupivacaine. Liposomal bupivacaine can potentially provide pain relief lasting up to 72 hours while regular bupivacaine can provide pain relief up to 12 hours

Detailed Description
-----------------
Patients undergoing hip arthroscopy experience moderate to severe postoperative pain. Effective pain control after surgery is an important component in the overall management of these patients. Good pain control encourages early participation in rehabilitation program, increases success of the surgery, and improves patient satisfaction. Typically, postoperative analgesia is provided to these patients either with nerve blocks or opioid medications. Both these methods provide good pain relief but nerve blocks are associated with weakness of lower extremity muscles which interferes with early ambulation and increase the risk of falls while narcotic medications increase the risk of nausea, vomiting, itching, constipation, ileus, urinary retention, sedation and respiratory depression.

Official Title
-----------------
Comparison of Bupivacaine to Liposomal Bupivacaine for Ultrasound Guided Periarticular Hip Infiltration for Postoperative Analgesia After Hip Arthroscopy.

Conditions
-----------------
Hip Injuries

Intervention / Treatment
-----------------
* Drug: liposomal bupivacaine
* Drug: Bupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients having hip arthroscopy Exclusion Criteria: History of neurologic disease, neuropathy, diabetes Allergy to local anesthetic solution Chronic use of narcotics Inability to give consent/cooperate with study History of previous hip arthroscopy on the ipsilateral side Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Liposomal bupivacaine<br>Ultrasound guided injection of liposomal bupivacaine for patients undergoing hip arthroscopy | Drug: liposomal bupivacaine<br>* (Ultrasound guided injection of liposomal bupivacaine) for patients undergoing hip arthroscopy<br>* Other names: Exparel;|
| Active Comparator: Bupivacaine<br>Bupivacaine (around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy | Drug: Bupivacaine<br>* (around the anterior, lateral and medial aspect of hip joint) for patients undergoing hip arthroscopy<br>* Other names: Marcaine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Opioid Consumption (Mean Number of 5mg Oxycontin Tablets Consumed) | Consumption of 5mg Oxycontin tablets will be assessed on Post Operative Days 1, 2 & 3. | Post Operative Day 1, 2 & 3 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Scores | Analysis of pain scores (at rest and ambulation) during hospital stay. Measured on a 10 point pain scale (1 being no pain and 10 being worst pain imaginable) | Post Operative Day 1, 2 & 3 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hip Arthroscopy, Liposomal Bupivacaine, Bupivacaine